赵红侠 李向欣 董伟 王佳 庞宇

【摘要】 目的：分析米力農注射液结合前列地尔注射液对慢性阻塞性肺疾病（COPD）合并肺心病患者疗效、肺功能及血清肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）水平的影响。方法：选取2018年10月-2020年6月于本院就诊并进行治疗的COPD合并肺心病患者90例。按照随机抽签法将90例患者分为观察组和对照组，每组45例。对照组进行常规治疗+米力农注射液治疗，观察组在对照组基础上给予前列地尔注射液治疗，两组均治疗7 d。观察并对比两组临床疗效与不良反应发生情况，比较两组治疗前后的肺功能、血气分析指标、心率及血清CK、CK-MB水平。结果：观察组总有效率为95.56%，明显高于对照组的80.00%（P<0.05）。两组治疗前肺功能指标比较，差异均无统计学意义（P>0.05）。观察组治疗后FEV1、FVC、FEV1/FVC%、肺动脉压水平均明显优于对照组（P<0.05）。两组治疗前血气分析、心率比较，差异均无统计学意义（P>0.05）。观察组治疗后PaO2、PaCO2、心率水平均明显优于对照组（P<0.05）。两组治疗前血清CK、CK-MB水平比较，差异均无统计学意义（P>0.05）;观察组治疗后血清CK、CK-MB水平均明显优于对照组（P<0.05）。观察组不良反应发生率为11.11%，对照组为8.89%，两组比较差异无统计学意义（P>0.05）。结论：米力农注射液结合前列地尔注射液对COPD合并肺心病患者的治疗效果较好，可明显改善患者的肺功能、血气分析指标、生命体征及血清CK、CK-MB水平，安全性较高，值得应用。

【关键词】 米力农注射液 前列地尔注射液 COPD 肺心病 肺功能 CK CK-MB

Effect of Milrinone Lactate Injection Combined with Alprostadil Injection on Curative Effect， Lung Function and Serum CK， CK-MB Levels in Patients with COPD Complicated with Pulmonary Heart Disease/ZHAO Hongxia， LI Xiangxin， DONG Wei， WANG Jia， PANG Yu. //Medical Innovation of China， 2021， 18（33）： 0-032

[Abstract] Objective： To analyze the effect of Milrinone Lactate Injection combined with Alprostadil Injection on curative effect， lung function and serum creatine kinase （CK） and creatine kinase isoenzyme （CK-MB） in patients with COPD complicated with pulmonary heart disease. Method： From October 2018 to June 2020， 90 patients with COPD complicated with pulmonary heart disease were selected， according to the random drawing method， 90 patients were divided into the observation group and the control group， 45 cases in each group. The control group was treated with conventional treatment + Milrinone Lactate Injection， and the observation group was treated with Alprostadil Injection on the basis of the control group， two groups were treated for 7 d. The clinical efficacy and occurrence of adverse reactions of two groups were observed and compared， and the lung function， blood gas analysis indexes， heart rate， serum CK and CK-MB levels of two groups before and after treatment were compared. Result： The total effective rate of the observation group was 95.56%， which was significantly higher than 80.00% of the control group （P<0.05）. There were no significant differences in lung function indexes between two groups before treatment （P>0.05）. The levels of FEV1， FVC， FEV1/FVC% and pulmonary artery pressure of the observation group after treatment were significantly better than those of the control group （P<0.05）. There were no significant differences in blood gas analysis and heart rate between two groups before treatment （P>0.05）. The PaO2， PaCO2 and heart rate of the observation group after treatment were significantly better than those of the control group （P<0.05）. There were no significant differences in serum CK and CK-MB levels between two groups before treatment （P>0.05）. The serum CK and CK-MB levels of the observation group after treatment were significantly better than those of the control group （P<0.05）. The incidence of adverse reactions in the observation group was 11.11%， the control group was 8.89%， and there was no significant difference between two groups （P>0.05）. Conclusion： Milrinone Lactate Injection combined with Alprostadil Injection has a good therapeutic effect on patients with COPD complicated with pulmonary heart disease， which can significantly improve the lung function， blood gas analysis indexes， vital signs and serum CK， CK-MB levels， with high safety， and it is worthy of application.

[Key words] Milrinone Lactate Injection Alprostadil Injection COPD Pulmonary heart disease Lung function CK CK-MB

First-author’s address： Changping District Hospital， Beijing 102200， China

doi：10.3969/j.issn.1674-4985.2021.33.008

COPD是临床上一种呼吸系统常见的疾病，其发病率、病死率均较高，主要症状为持续存在的气流受限以及相关的呼吸系统症状，病情呈现进行性发展，主要与肺部组织对有害的气体或颗粒等异常的炎症反应有关，对患者劳动能力、生活质量以及生命安全产生重大影响[1-3]。……